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RESUMEN 
Objetivo: El propósito del presente estudio es desarrollar un gel nasal sensible a iones de clorhidrato de 
Fluoxetina (FXH) para el suministro cerebral. Se utilizó un diseño factorial 32 para investigar el efecto de 
la variable independiente en las variables dependientes.
Métodos: Se evaluaron las formulaciones para el estudio de gelificación, viscosidad, resistencia de gel, 
fuerza de mucoadhesión, contenido de fármaco, permeabilidad in vitro de fármacos, estudio farmacod-
inámico in vivo y estudio de estabilidad.
Resultados: Los resultados revelaron que a medida que aumentaba la concentración de goma de gelano 
y HPMC, había un incremento en la viscosidad y resistencia a la mucoadhesión y disminución en el 
porcentaje de liberación. La formulación F4 optimizada mostró la liberación de fármaco más alta del 
94,24%. En el estudio de actividad locomotora y prueba de natación forzada, las ratas tratadas con gel 
in situ mostraron respuestas significativas en comparación con el grupo de control. Los exámenes histo-
patológicos no mostraron evidencia de daño en la mucosa nasal. El gel nasal in situ fue estable después 
de 3 meses.
Conclusión: Se concluyó que las formulaciones nasales de clorhidrato de fluoxetina que mejoraban la 
absorción nasal y la conformidad del paciente para el tratamiento de la depresión.
Palabras clave: Absorción nasal, clorhidrato de Fluoxetina, Farmacodinámico
ABSTRACT 
Objective: The purpose of the present study is to develop an ion sensitive in situ nasal gel of Fluoxetine 
hydrochloride  for brain delivery. A 32 factorial design was used to investigate effect of independent 
variable on dependent variables. 
Methods: Formulations were evaluated for gelation study, viscosity, gel strength, mucoadhesion 
strength, drug content, ex-vivo drug permeation, in vivo pharmacodynamic and stability study. 
Results: The results revealed that as the concentration of gellan gum and HPMC were increased, there 
was increase in viscosity and mucoadhesive strength and decrease in percent release. The optimized for-
mulation F4 showed highest drug release 94.24 %. In locomotor activity and forced swim test study, the 
in situ gel treated rats showed significant responses as compared to control group. Histopathological ex-
aminations showed no evidence of nasal mucosal damage. The in situ nasal gel was stable after 3 months. 
Conclusion: It was concluded that, the in situ nasal formulations of Fluoxetine hydrochloride  which 
enhanced nasal absorption and patient compliance for the treatment of depression.
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INTRODUCTION
Depression is a common psychiatric disorder, and statistics 
clearly identify it as a major public health problem1. The 
major disadvantage with conventional dosage forms are 
many patients find it difficult to swallow (dysphagia) tab-
lets and capsules2. Nose to brain delivery has number of 
advantages, such as drugs can be rapidly absorbed through 
the nasal mucosa, giving rapid onset of action. The olfacto-
ry region of nasal mucosa that provides a direct connection 
between nose and brain can be exploited for targeting cen-
tral nervous system (CNS)-acting enormous range of drug 
molecules of neurotherapeutics, both macromolecules and 
low molecular weight drugs, used in conditions such as 
Alzheimer’s disease, depression, migraine, schizophrenia5. 
Both hydrophobic drugs, e.g. propranolol7 and hydrophilic 
drugs, e.g. vanlafaxine hydrochloride8 are absorbed by the 
nasal mucosa. The gellan gum is an ion sensitive polymer 
which forms clear gel in contact with monovalent and di-
valent cations. In an ion free aqueous medium, it forms 
double helices which at room temperature are only weak-
ly attached to each other (van der Waals attraction). In the 
presence of cations some of the helices associate into aggre-
gates and cause cross-linking of the polymer chains9. Fluox-
etine hydrochloride (FXH) is a selective serotonin reuptake 
inhibitor as an antidepressant, is widely used to treat var-
ious types of psychiatric disorders1011. The dose of FXH 
ranges from 20 to 80 mg administered as 1 to 4 capsules a 
day. This dose and frequency may cause enhanced drug-re-
lated side effects and may pose compliance problems12. The 
long half-life of fluoxetine and its active metabolite essen-
tially preclude a withdrawal phenomenon. It is an inhibi-
tor of cytochrome P450 (CYP)2D6 and other CYP enzymes, 
which increases the potential for drug interactions and also 
undergoes extensive hepatic first-pass metabolism13-15. The 
objective of the present work was to prepare in situ gel of 
FXH for enhanced drug absorption in brain through nasal 
route and patient compliance for the treatment of depres-
sion.
MATERIALS AND METHODS 
Materials
 (FXH) was obtained from Swapnaroop drugs and chem-
icals, Aurangabad. Gellan gum (Gelrite) was procured as 
gift samples from Signet Chemical Corporation Ltd. Hy-
droxypropyl methylcellulose (HPMC) were obtained as a gift 
sample from Colorcon, Mumbai, India. Mannitol and pro-
pyl paraben were obtained from Molychem India, Mumbai.
Methods
In the present study 32 full factorial designs (Design Ex-
pert 7.0.0.0) was selected to obtain nine formulation and to 
study the effect of independent variables gellan gum (X1) 
and HPMC (X2) on dependent variables such as viscosity, 
mucoadhesive strength and drug release.  
Preparation of in situ gel
Gellan gum and HPMC was weighed and dispersed sep-
arately in distilled water and stirred by mechanical stirrer 
(Remi motors Ltd, Mumbai, India, type RQ-122) for 30 min 
at 90oC in a water bath and then cooled to room temper-
ature. FXH (1% w/v) and HPMC solution was added in 
gellan gum solution slowly with continues stirring. Appro-
priate quantities of mannitol as a osmotic agent and propyl 
paraben were added simultaneously 16. The compositions 
of prepared formulations of FXH are shown in (Table 1).
Table 1: The compositions of prepared formulations of FXH 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Fluoxetine HCl (%) 1 1 1 1 1 1 1 1 1
Gellan gum (%) 0.2 0.2 0.2 0.4 0.4 0.4 0.6 0.6 0.6
HPMC (%) 0.1 0.15 0.2 0.1 0.15 0.2 0.1 0.15 0.2
Mannitol (%) 4 4 4 4 4 4 4 4 4
Propyl paraben (%) 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Distilled water (q.s) ml 100 100 100 100 100 100 100 100 100
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Gelation study
The gelation study was done by taking formulation and 
simulated nasal fluid SNF (1:1v/v ratio) and mixed on mag-
netic stirrer (Magnetic stirrer, Remi). The gelation point was 
determined when the magnetic bar stopped moving due to 
gelation17. The consistency of formed gel was checked and 
graded, as indicated in (Table 2).
Viscosity study
The viscosity of nasal formulation before and after gela-
tion was determined using Brookfield Rheometer R/S-CPS 
+1600 (Lauda Ecoline Staredition RE-204). Each point is the 
average of at least three readings18.
Gel strength study
Test was performed using a gel strength apparatus mod-
ified at the laboratory. In situ gel formulation (50 g) was 
placed in a 100 ml measuring cylinder and gelation was 
induced by simulated nasal fluid. The apparatus for meas-
uring gel strength (weight: 35 g) was then placed on the gel. 
The gel strength was measured by the minimal weight that 
pushed the apparatus 5 cm down through the gel19.
Mucoadhesive strength study
Fresh nasal mucosa was obtained from the local slaughter 
house (Aurangabad), was carefully removed from the nasal 
cavity of sheep and mounted on glass surface using adhe-
sive tape while another mucosal section was fixed in in-
verted position to the cylinder. 50 mg of gel was placed on 
mucosal surface. The glass mounted mucosal surface with 
gel formulation and mucosal surface attached to cylinder 
were held in contact with each other for 2 min to ensure 
intimate contact between them. In second pan, the weights 
were increased until the two mucosal tissues got detached 
from each other. The nasal mucosa was changed for each 
measurement. The mucoadhesive force expressed as the 
detachment stress in dynes/cm2 was determined from the 
minimal weight that detached the mucosal tissue from sur-
face of each formulation20.
Mucoadhesive strength (dynes/cm2) = mg/A 
Where, 
m = Weight required for detachment in gram, 
g = Acceleration due to gravity (980 cm/s2),
A = Area of mucosa exposed.
Drug content
The drug content was determined by taking 1ml of formu-
lation in a 50 ml volumetric flask diluted with phosphate 
buffer pH 6.6 and analyzed using UV-visible spectropho-
tometer (Shimadzu, UV-1800, Lab India) at λmax 263.80 nm.
Ex-vivo permeation study 
Ex-vivo permeation study of formulations was carried out 
using Franz diffusion cell. Nasal mucosa was placed in dif-
fusion cells displaying a permeation area of 0.785 cm². The 
receiver compartment containing phosphate buffer pH 6.6 
as in range of nasal cavity pH was maintained at 37 ±0.5°C. 
After a pre-incubation time of 20 min, formulation equiv-
alent to 10 mg of FXH was placed in the donor chamber 
containing 3 ml of artificial nasal fluid. At predetermined 
time points (30, 60, 120, 180 and 240 min), 1ml of sample 
was withdrawn from the receptor compartment, replacing 
with fresh medium21. The amount of drug permeated was 
determined using UV-visible spectrophotometer (Shimad-
zu, UV-1800, Lab India) at λmax 263.80 nm.
Release mechanism
To study the mechanism of drug release from prepared 
gelling system, the in vitro permeation data were fitted to 
zero order, first order, Higuchi release model, Hixson and 
Crowell method and Korsemeyer-Peppas model by using 
DD Solver software, and the model with the higher correla-
tion coefficient was considered to be the best model22.
Histopathological study
Histopathological examination on control mucosa and F4 
formulation treated mucosa was performed using a light 
microscope (Nikon Eclipse E600, Japan). Tissue was fixed 
with 10% buffered formalin (pH 7.0), routinely processed 
and embedded in paraffin. Sections (5μm) were cut on glass 
slides and stained with hematoxylin and eosin.
Stability study
The stability study as per ICH guideline on optimized for-
mulation F4 was carried out at, temperature 400 C ± 2 ºC 
and humidity 75% RH ± 5% condition in stability chamber 
(HMG, India) for three months. The formulation was exam-
ine for pH, drug content, viscosity23.
In vivo pharmacodynamic study
IAEC, M.E.S. College of Pharmacy, Sonai approved the 
protocol for In vivo pharmacodynamic study. Locomotor 
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activity test (LAT) and Forced swim test (FST) was carried 
out to evaluate the antidepressant effect of the optimized 
F4 formulation. Rats of either sex weighing 250–300 g were 
selected and kept under standard laboratory conditions 
(temperature 23-300C) with free access to standard labora-
tory diet. Rats were divided randomly into three groups, 
each containing six animals (n= 6). Group one was treat-
ed with saline and was considered as a control. Group two 
was treated with oral tablets of FXH containing dose of 10 
mg/kg. Group three was treated with optimized F4 formu-
lation through nasal containing 10 mg/kg. The doses were 
administered without anesthesia by using simple poly-eth-
ylene tube.
Force swim test
The tank was filled 90 % with water so they swim without 
touching their hind limb or tail to the bottom of the tank. 
On day one of experiments, rats were forced to swim for 10 
min. After 24 h, rats were re-exposed to forced swim after 
administration of dose for 5 min and animals were judged 
for immobility, climbing, and swimming and experiments 
were performed for thrice. After experiment, the rat was 
removed from the tank and returned to their cage 24 
Locomotor activity test
Locomotor activity was measured in the open-field test. 
The apparatus consisted of a square arena (200×200 cm), 
with a 50 cm height. The floor was divided into 30 equal 
squares. Animals were individually positioned in the 
center of the arena and the activity was measured over 5 
min (numbers of square crossed). A square crossed was 
defined as the rat placing its four paws into the quadrant 
and going to the neighboring quadrant. The open field was 
cleaned with isopropyl alcohol solution before behavioral 
testing to avoid possible bias due to odors and/or residues 




Statistical model incorporating interactive and polynomial 




Where, Y is the dependent variable, b0 is the arithmetic 
mean response of the nine runs and b1 (b1, b2, b12, b11 
and b22) is the estimated coefficient for the corresponding 
factor X1 (X1, X2, X12, X11 and X22), which represents the 
average results of changing one factor at  a time from its 
low to high value. The interaction term (X1X2) depicts the 
changes in the response when two factors are simultane-
ously changed.  
Y (Viscosity) =66.44+9.57X1+27.93X2 
From above equation the positive coefficient of variable X1 
and X2 indicate that, as concentration of gellan gum and 
HPMC increased the viscosity was also increased. 
Y(Mucoadhesive strength) =+2564.26+208.89 X1+290.78 X2-
5.25 X1 X2+80.45 X1
2 4.89 X2
2 
From above equation the positive coefficient of variable X1 
and X2 indicate that, as concentration of gellan gum and 
HPMC increased the mucoadhesive strength was also in-
creased. 
Y(% drug release) = +86.88 -2.40 X1-6.95 X2
From above equation the negative coefficient of combine 
variable X1 and X2 indicate that as concentration of gellan 
gum and HPMC increased the percent drug release de-
crease. 
Response surface plot (RSP)
From RSP evaluation it was found that concentration of 
gellan gum and HPMC increased, mucoadhesive strength 
and viscosity increases. Where as in case of drug release 
concentration of polymer increases the permeation release 
decreases as shown in Figure 1. The RSP results were simi-
lar to the mathematical data.
Gelation study
In gelation study, it was observed that as concentration of 
gellan gum increased (0.2 to 0.6 %) gelation point increased. 
The formulation F1 to F3 showed less gelation point where-
as F4 to F6 showed immediate gelation remain for few 
hours (less stiff gel). Further as concentration of gellan gum 
increased the immediate gelation remain for extended pe-
riod (stiff gel). Gelation was assessed on a scale ranging be-
tween - and +++, as shown in (Table 2). From above results, 
it revealed that the HPMC did not affect the gelation phe-
nomena, but the gellan gum plays a critical role in hydrogel 
formation.
Viscosity study
In viscosity study it was found that as concentration of 
gellan gum and HPMC increased, the viscosity goes on in-
creasing. Formulation F1 to F9 the concentration of HPMC 
increased (0.1 to 0.2%) and gellan gum (0.2 to 0.6 %), the 
viscosity increased before and after gelation as shown in 
Table 2.
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Figure 1. Response surface plot for viscosity, mucoadhesive strength and drug release
Gel strength
The results of all formulations had gel strength between 
18.67 sec to 56.67 sec as shown in (Table 2). The formulation 
F1 and F2 showed the less gel strength and may not retain 
its integrity and erode rapidly, whereas F3 to F7 show the 
gel strength in range 27.33 sec to 47.67 sec, remain stable 
and retain its integrity. In formulation F8 and F9 showed 
gel strength more than 50 sec which may form stiff gel and 
caused discomfort to nasal mucosa. Gel strength above 50 
seconds suggests undesirable stiffness of gel formulation 
which may lead to irritation and discomfort in drug deliv-
ery. The gel strength values ranging 25-50 sec are consid-
ered adequate 26.  
Mucoadhesive strength study
Study indicates that, the concentration of HPMC increas-
es the mucoadhesive strength goes on increasing shown in 
(Table 2). HPMC is a hydrophilic polymer with many polar 
functional groups. Upon hydration the polymeric chains of 
HPMC get entangled with glycoprotein chains of mucin re-
sulting in bioadhesion 2728. 
Drug content
The drug content was in the range 98.03- 101.07 %, which 
revealed that FXH was uniformly dispersed in gelling sys-
tem. The results are shown in (Table 2).
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F1 + 33.16±0.3 101.43± 2.25 18.67±0.58 2135±2.65 98.67±0.53 80.52±3.2
F2 + 39.06±0.6 112.198± 5.86 24±1.0 2446.67±2.08 98.03±0.73 74.50± 4.5
F3 + 47.80±0.3 124.683±8.52 27.33±0.58 2716±3.46 99.28±0.29 70.02± 5.8
F4 ++ 54.35±0.2 143.39±7.52 31±1.0 2282±2.65 99.79±0.29 94.24±2.6
F5 ++ 63.67±0.5 164.99± 8.45 34±1.0 2515.33±0.58 100.16±1.10 85.52±5.4
F6 ++ 72.31±0.5 182.82± 5.23 42.33±1.53 2885.67±2.52 99.66±1.25 80.12±3.4
F7 +++ 82.75±0.3 197.71± 8.52 47.67±2.08 2549.67±2.08 101.07±0.36 82.18±4.5
F8 +++ 97.26±0.3 220.43± 6.24 52.33±0.58 2891.67±1.53 99.13±0.29 80.12±5.4
F9 +++ 107.60±0.8 237.15± 10.23 56.67±2.08 3109.67±2.52 99.80±0.25 75.10±5.7
Ex-vivo permeation study
The results reveal that as the concentration of gellan gum 
(0.2 to 0.6%) and HPMC (0.1 to 0.2 %) increased, the drug 
release was decreased. The percentage drug permeated af-
ter 240 min from all formulations was found to be between 
75.10 to 94.24%. The highest drug release was found in 
F4 formulation (94.24%), which was selected as optimum 
formulation for further study. Permeation profiles for all 
formulations are shown in (Figure 2). The initial rates of 
permeation were very rapid due to incomplete gel forma-
tion, but as the time progress the permeation rate decreases 
due to complete gel formation. With an increase in con-
centration of HPMC (0.1 to 0.2 %), the diffusion rates were 
found to decrease gradually. It was proposed that as the 
concentration of gellan gum increased, the polymer chains 
approached closer, and the number of interactions between 
the polymer chains increases which leads to a denser 3-D 
network structure29. Decreased in drug released might be 
due to the increase in polymer concentration which increas-
es the viscosity of gel layer with longer diffusional path 
length, resulting in greater retardation of drug in gel.
Release mechanism
The results obtained from release kinetics it could be con-
cluded that, the formulations (F1 to F9) exhibited n values 
between 0.542–0.986 indicating an anomalous or nonficki-
an release suggesting a coupled erosion– diffusion mecha-
nism.
Figure 2. Permeation profile of all formulations through sheep nasal mucosa
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Histopathological study
Intact columnar structure of epithelial cell was observed in 
both nasal mucosa (treated and untreated) shown in Figure 
3A. From results it was found that prepared formulation is 
safe to use.
Figure 3.
A). Histopathological image of sheep nasal mucosa  
A-treated, B- untreated. B). Results of forced swim test.
In vivo pharmacodynamic study
Force swim test
The FST is most used tool for screening antidepressants 
activity24. The F4 administer nasal route reduced total 
immobility period and increase climbing and swimming 
behavior as compared to control, orally administer group 
as shown in Figure 3B. This might be due to the required 
amount of FXH available in brain through nasal route.
Locomotor activity study
In study, difference in the values was found in control, oral-
ly administer and F4 formulation treated group through 
nasal as shown in Table 3. The results revealed that animals 
were not hyperactive.
Stability Study
In stability study there was no change found in drug con-
tent, pH and viscosity as shown in (Table 4). From stability 
study results, it was concluding that prepared formulation 
is stable.   





0 99.79±0.29 5.81±0.02 54.35±0.24
30 99.34±0.11 5.80±0.06 56.12±0.09
60 99.03±0.06 5.80±0.09 57.39±0.17
90 98.87±0.13 5.78±0.15 58.60±0.11
Table 4.  Results of locomotor activity.
Treatment group No of square crossed
Mean ± 
SD, 
n =  3
Control 74±2 78±4 76±2 77±2
F4 Formulation 86±3 87±3 86±3 87±2*
Oral administration 85±2 84±3 85±2 84±3
Values are expressed in mean ± SD, n =  3 , *p value < 0.05 
considered statistically significant compared to control
CONCLUSION
A 32 factorial design was used successfully to study the ef-
fect of different variables. The optimized formulation F4 
containing 0.4% gellan gum and 0.1% HPMC showed high-
est drug release (94.24 %) through sheep nasal mucosa. In 
pharmacodynamic study, the in situ gel treated rats showed 
significant responses as compared to control group. It was 
concluded that, the in situ nasal formulations of FXH was 
effectively formulated using quality by design approach 
which enhanced drug absorption in brain through nasal 
route and patient compliance for the treatment of depres-
sion.
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